Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

This study has been terminated.
(slow accrual)
Sponsor:
Collaborators:
Genentech
Novartis
Information provided by (Responsible Party):
Sandy Srinivas, Stanford University
ClinicalTrials.gov Identifier:
NCT00651482
First received: March 28, 2008
Last updated: June 30, 2014
Last verified: June 2014
  Purpose

To determine the safety and efficacy of the combination of bevacizumab and everolimus (RAD001) for the treatment of metastatic renal cell cancer


Condition Intervention Phase
Kidney Neoplasms
Kidney (Renal Cell) Cancer
Drug: Everolimus
Drug: Bevacizumab
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Progression-free Survival (PFS) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) per RECIST criteria


Secondary Outcome Measures:
  • Objective Response (OR) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Number of subjects with objective response (OR)

  • Objective Response (OR) Duration [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Time-to-Treatment Failure (TTF) [ Time Frame: 24 months ] [ Designated as safety issue: No ]
  • Overall Survival (OS) [ Time Frame: 44 months ] [ Designated as safety issue: No ]
  • Number of Subjects With Drug-related SAEs [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Total Number of Drug-related SAEs [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
  • Treatment Discontinuation Due to Toxicity [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]
    Number of subjects whose treatment was discontinued due to toxicity

  • Treatment Discontinuation Due to Disease Progression [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    Number of subjects whose treatment was discontinued due to disease progression


Enrollment: 10
Study Start Date: August 2008
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab + RAD001 (everolimus)

Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles

Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)

Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)

Drug: Everolimus
Other Names:
  • Zortress
  • Certican
  • RAD001
Drug: Bevacizumab
Other Name: Avastin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Informed Consent Form
  • Histologically confirmed metastatic RCC that is predominantly clear cell Measurable disease, as defined by RECIST
  • Age ≥ 18 years
  • ECOG performance status of 0 or 1
  • No more than 1 prior targeted therapy (eg, sorafenib, sunitinib) (prior cytokine therapy allowed)
  • No more than 2 prior systemic therapies
  • Ability and capacity to comply with the study and follow-up procedures

General Exclusion Criteria

  • Inability to comply with study and/or follow-up procedures
  • Life expectancy of < 12 weeks
  • Inadequate organ function, as evidenced by any of the following at screening:

    • Absolute neutrophil count (ANC) < 1500/uL
    • Platelet count ≤ 100 x 10^9/L
    • Total bilirubin ≥ 1.5 x upper limit of normal (ULN)
    • AST and/or ALT > 2.5 x ULN for patients without evidence of liver metastases, or 5 x ULN for patients with documented liver metastases
    • Serum creatinine > 2.0 mg/dL
    • Hemoglobin < 9 g/dL (may be transfused or receive epoetin alfa to maintain or exceed this level)
  • Active infection or fever > 38.5°C within 3 days of starting treatment
  • Women who are pregnant or breast feeding,
  • Able to conceive and unwilling to practice an effective method of birth control.
  • History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma, squamous-cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage bladder cancer, or low-grade endometrial cancer
  • Malignancies that have undergone a putative surgical cure (i.e., localized prostate cancer post-prostatectomy) within 5 years prior to Day 1 may be discussed with the Principal Investigator.
  • Any other medical conditions (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results.
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study

Disease-Specific Exclusion Criteria

  • RCC with predominantly sarcomatoid features
  • Radiotherapy for RCC within 28 days prior to Day 1, with the exception of single-fraction radiotherapy given for the indication of pain control
  • Prior treatment with bevacizumab or any mTOR inhibitor (eg, temsirolimus, sirolimus, or everolimus)
  • Current need for dialysis

Bevacizumab-Specific Exclusions

  • Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • History of myocardial infarction or unstable angina within 6 months prior to study enrollment
  • History of stroke or transient ischemic attack within 6 months prior to study enrollment
  • Known CNS disease, except for treated brain metastasis. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed appropriate by the treating physician. Patients with CNS metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will be excluded.
  • Significant vascular disease (eg, aortic aneurysm, aortic dissection)
  • Symptomatic peripheral vascular disease
  • Evidence of bleeding diathesis or coagulopathy that is not intentionally pharmacologically-induced
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
  • Serious, non-healing wound, ulcer, or bone fracture
  • Proteinuria at screening as demonstrated by a urine protein:
  • Creatinine (UPC) ratio ≥ 1.0. If UPC ratio ≥ 1.0, the patient must undergo a 24 hour urine collection which must demonstrate ≤ 1g of protein in 24 hours to be eligible.
  • Known hypersensitivity to any component of bevacizumab

RAD001-Specific Exclusion Criteria

  • Known hypersensitivity to any component of RAD001
  • Chronic treatment with systemic steroids or another immunosuppressive agent
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
  • Severely impaired lung function (spirometry and DLCO < 50% of normal and O2 saturation 88% or less at rest on room air)
  • If O2 saturation is ≤ 88% at rest on screening, pulmonary function tests (PFTs) will be ordered to confirm normal pulmonary function and eligibility.
  • Fasting total cholesterol > 350 mg/dL
  • Fasting triglyceride level > 400 mg/dL or >2.5 x ULN
  • Fasting serum glucose > 250 mg/dL
  • Serum phosphorus < 2.0 mg/dL
  • Serum corrected calcium < 8.0 mg/dL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00651482

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Sandy Srinivas
Genentech
Novartis
Investigators
Principal Investigator: Dr. Sandy Srinivas Stanford University
  More Information

Publications:
Responsible Party: Sandy Srinivas, Associate Professor, Stanford University
ClinicalTrials.gov Identifier: NCT00651482     History of Changes
Other Study ID Numbers: IRB-11789, RENAL0016, 98593, AVF4304s, 41839
Study First Received: March 28, 2008
Results First Received: June 30, 2014
Last Updated: June 30, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adenocarcinoma
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Everolimus
Sirolimus
Bevacizumab
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on July 31, 2014